Vaccines

Patient receiving vaccine
#Clinical trials #Covid-19 #Immunology / Virology & Vaccines #Vaccines

Sanofi and GSK Covid-19 vaccine to progress to Phase III trials

The Sanofi and GSK adjuvanted recombinant Covid-19 vaccine candidate achieved strong rates of neutralising antibody responses, in line with those measured in people who have recovered from Covid-19, in all adult age groups in a Phase II study with 722 volunteers. The Phase II interim results showed 95% to 100%… Read More

#Covid-19 #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines #mRNA #Vaccines

CureVac GSK Covid-19 vaccine candidate shows high immunogenicity

CureVac, in collaboration with GSK, has announced that its second-generation Covid-19 vaccine candidate, CV2CoV, induces high levels of antigen production as well as strong and dose-dependent immune responses in vaccinated animals. CV2CoV is a co-development between CureVac and GSK and is based on a new mRNA backbone, which differs from… Read More

#Covid-19 #News

#Cancer research #Drug targets #Immuno-oncology #Oncology #Research #Vaccines

Personalised cancer vaccine 45% effective at targeting tumours

Researchers have developed an effective vaccine that re-engineers cells from a patient’s tumour to target and destroy cancer cells. The results, published in the peer-reviewed Journal of Clinical Oncology, show that 45% of patients treated with an autologous cell vaccine, created from their own cancer cells, had a confirmed anti-tumour… Read More

#News

#Covid-19 #Immunology / Virology & Vaccines #Research study #Vaccines

Is this the solution to increasing Covid-19 vaccine uptake?

The largest ever study of Covid-19 vaccine messaging shows that emphasising the personal benefits rather than collective of vaccination may be the most effective way to persuade people who are sceptical. Researchers from the University of Oxford, funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre… Read More

#Covid-19 #News #Trending News

#Biopharmaceutical #Covid-19 #Life sciences #Pharmaceutical research #Vaccines

ABPI chief stresses importance of research investment

The Chief Executive of the UK’s Association of the British Pharmaceutical Industry (ABPI), Richard Torbett, has stressed the importance of investment in research in response to the Queen’s Speech delivery. “The response to the pandemic has shown just how critical the UK’s pharmaceutical industry is to our country’s future and… Read More

#News #Trending News

#Covid-19 #Drug delivery #Immunology / Virology & Vaccines #Moderna #Vaccines

500 million Covid-19 vaccine doses delivered to lowest income countries

Moderna has announced an agreement with Gavi, the Vaccine Alliance to supply up to 500 million doses of the Covid-19 Vaccine Moderna, including an initial 34 million doses to be delivered in the fourth quarter of 2021. Through this agreement, on behalf of the COVAX Facility, Gavi also retains… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines #Moderna #mRNA #Vaccines

Moderna invests to increase global supply for Covid-19 vaccine

Moderna is to increase supply at its manufacturing facilities, which it expects will increase global 2022 capacity to up to 3 billion doses of its Covid-19 vaccine. This will depend upon the mix between the authorised Moderna Covid-19 vaccine at the 100 μg dose level and potentially lower… Read More

#News

#Biopharmaceuticals #Covid-19 #Drug delivery #Drug development #Drug discovery #Drug innovation #Immunology / Virology & Vaccines #Pharma #Pharmaceuticals #Vaccines

Integration at its best: Dalton Pharma outlines its CDMO expertise

Dalton Pharma Services, a contract development and manufacturing organisation (CDMO) offers expertise in drug discovery, formulation and process development, custom synthesis, and GMP manufacturing services. Lu Rahman spoke to CEO, Peter Pekos about the company’s ongoing expertise. LR: The company has experience supplying the needs of the orphan drug field… Read More

#Exclusive Content #News #Opinion

#Covid-19 #Immunology / Virology & Vaccines #Research #Vaccines

Covid-19 vaccine responses to be studied in people with immune deficits

A study assessing how people with immune system deficiencies or dysregulations respond to Covid-19 vaccination has begun enrolling participants at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. The single-site study is led by researchers from the National Institute of Allergy and Infectious Diseases (NIAID) and aims… Read More

#News

Mosquito
#Clinical trial #Immunology / Virology & Vaccines #Malaria #Research #Vaccines

Malaria vaccine first to achieve WHO-specified 75% efficacy goal

Researchers from the University of Oxford and their partners have reported findings from a Phase IIb trial of a candidate malaria vaccine, R21/Matrix-M, which demonstrated high-level efficacy of 77% over 12-months of follow-up. In their findings (posted on SSRN/Preprints with The Lancet), they note that they are the first to… Read More

#News

#Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #mRNA #Pfizer #Vaccines

Evonik delivers first lipids to BioNTech ahead of schedule

Chemical specialist Evonik is helping to accelerate the production of the Covid-19 vaccine from Pfizer-BioNTech by suppling an essential component. Evonik is delivering first batches of urgently needed lipids for the mRNA-based vaccine to BioNTech months earlier than anticipated. Specialists at Evonik’s Hanau site set up the lipid production in… Read More

#Covid-19 #News

#Biologics #Cell / tissue culture #Covid-19 #Vaccines

Biden administration unblocks access to federal funded fetal tissue cells

A notice released by the US National Institutes of Health (NIH) on April 16, 2021 revealed that the Biden administration has reversed restrictions set in 2019 by the Trump administration on federal funding for medical research and biomedical studies by government employees using human fetal tissue from elective abortions. Health.com… Read More

#News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines #Vaccine candidate #Vaccines

Novavax to participate study comparing mixed Covid-19 vaccines 

Novavax has announced its participation in a newly expanded investigator-initiated Phase II clinical trial called Comparing Covid-19 Vaccine Schedule Combinations – Stage 2 (Com-COV2), to be conducted by the University of Oxford and supported by the UK Vaccines Taskforce. Novavax’ recombinant protein vaccine candidate, NVX-CoV2373, is one of four Covid-19… Read More

#Covid-19 #News

#Antibodies #Covid-19 #Drug development #Drug discovery #Therapies #Vaccines

Covid-19 response speed sets a new standard in drug discovery

    This paid-for advertorial by Berkeley Lights appeared in DDW Volume 22, Issue 2 – Spring 2021 The Covid-19 pandemic has illuminated how a coordinated response to infectious diseases can result in the development and commercialisation of novel vaccines and therapies at record pace. Several therapeutic antibodies and vaccine… Read More

#Covid-19 #Exclusive Content

#Antibodies #Immune system #Vaccine candidate #Vaccines

How a soccer ball and a computer inform new vaccines

RSV is a complicated virus, and traditional vaccine methods have not worked. But UW’s Institute for Protein Design may have solved the problem using computational design. With the help of an innovative computer program, Icosavax has constructed virus-like particles (VLPs) using a two-part assembly (like a soccer ball). Adam Simpson,… Read More

#Editor's Choice #Exclusive Content #Intelligence #News #Opinion #Start-up Zone